Characterization and quantitation of aggregates and particles in interferon-β products: Potential links between product quality attributes and immunogenicity

Journal of Pharmaceutical Sciences

Volumn 102, Issue 3, 2013, Pages 915-928

  Barnard, James G ^a   Babcock, Ken ^b   Carpenter, John F ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b Affinity Biosensors   (United States)

Author keywords

Analytical ultra centrifugation; Biopharmaceuticals characterization; Immunogenicity; Interferon beta; Microparticles; Nanoparticles; Protein aggregation; Proteins; Subvisible particles

Indexed keywords

BETA1A INTERFERON; HUMAN SERUM ALBUMIN; INTERFERON BETA SERINE; MONOMER; NEUTRALIZING ANTIBODY; SILICONE OIL;

ARTICLE; BLOTTING; CONTROLLED STUDY; GEL ELECTROPHORESIS; GEL PERMEATION CHROMATOGRAPHY; IMMUNOASSAY; IMMUNOGENICITY; MOLECULAR WEIGHT; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; ULTRACENTRIFUGATION;

EID: 84878149778     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23415     Document Type: Article

References (42)

1. van Beers MM, Jiskoot W, Schellekens H. 2010. On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis. J Interferon Cytokine Res 30(10):767-775.
2. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR. 2007. Interferons at age 50: Past, current and future impact on biomedicine. Nat Rev Drug Discov 6(12):975-990.
3. Giovannoni G, Munschauer F, Deisenhammer F. 2002. Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 73(5):465-469.
4. 1996. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: Experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neurology 47(4):889-894.
5. Grossberg SE, Oger J, Grossberg LD, Gehchan A, Klein JP. 2011. Frequency and magnitude of interferon beta neutralizing antibodies in the evaluation of interferon beta immunogenicity in patients with multiple sclerosis. J Interferon Cytokine Res 31(3): 337-344.
6. Rudick RA, Simonian NA, Alam JA, Campion M, Scaramucci JO, Jones W, Coats ME, Goodkin DE, Weinstock-Guttman B, Herndon RM, Mass MK, Richert JR, Salazar AM, 3rd Munschauer FE, Cookfair DL, Simon JH, Jacobs LD. 1998. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 50(5):1266-1272.
7. Hartung HP, 3rd Munschauer F, Schellekens H. 2005. Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: Expert opinions based on the Proceedings of an International Consensus Conference. Eur J Neurol 12(8):588-601.
8. Perini P, Facchinetti A, Bulian P, Massaro AR, Pascalis DD, Bertolotto A, Biasi G, Gallo P. 2001. Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo. Eur Cytokine Netw 12(1):56-61.
9. Gneiss C, Koudouovoh-Tripp PM, Ropele S, Gotwald T, Ehling R, Lutterotti A, Aichner F, Ladurner G, Eggers C, Schautzer F, Kunz B, Millonig A, Aspeck E, Reindl M, Berger T, Fazekas F, Deisenhammer F. 2009. Influence of interferon-beta therapy switching on neutralizing antibody titres: Results from the Austrian Switch Study. Mult Scler 15(12):1481-1488.
10. Hartung HP, Freedman MS, Polman CH, Edan G, Kappos L, Miller DH, Montalban X, Barkhof F, Petkau J, White R, Sahajpal V, Knappertz V, Beckmann K, Lanius V, Sandbrink R, Pohl C. 2011. Interferon beta-1b-neutralizing antibodies 5 years after clinically isolated syndrome. Neurology 77(9):835-843.
11. Bertolotto A, Deisenhammer F, Gallo P, Solberg Sorensen P. 2004. Immunogenicity of interferon beta: Differences among products. J Neurol 251 (Suppl 2):II15-II24.
12. Bozhinov A, Handzhiyski Y, Genov K, Daskalovska V, Niwa T, Ivanov I, Mironova R. 2011. Advanced glycation end products contribute to the immunogenicity of IFN-β pharmaceuticals. J Allergy Clin Immunol 129(3):855-858.
13. De Groot AS, Scott DW. 2007. Immunogenicity of protein therapeutics. Trends Immunol 28(11):482-490.
14. Chirino AJ, Ary ML, Marshall SA. 2004. Minimizing the immunogenicity of protein therapeutics. Drug Discov Today 9(2):82-90.
15. Braun A, Kwee L, Labow MA, Alsenz J. 1997. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm Res 14(10):1472-1478.
16. Moore WV, Leppert P. 1980. Role of aggregated human growth-hormone (Hgh) in development of antibodies to Hgh. J Clin Endocrinol Metab 51(4):691-697.
17. Henney CS, Ellis EF. 1968. Antibody production to aggregated human gamma-G-globulin in acquired hypogammaglobulinemia. N Engl J Med 278(21):1144-1146.
18. Biro CE, Garcia G. 1965. The antigenicity of aggregated and aggregate-free human gamma-globulin for rabbits. Immunology 8:411-419.
19. Weksler ME, Bull G, Schwartz GH, Stenzel KH, Rubin AL. 1970. Immunologic responses of graft recipients to antilymphocyte globulin: Effect of prior treatment with aggregate-free gamma globulin. J Clin Invest 49(8):1589-1595.
20. Tovey MG, Lallemand, C. 2011. Immunogenicity and other problems associated with the use of biopharmaceuticals. Ther Adv Drug Saf 2(3):113-128.
21. Sauerborn M, Brinks V, Jiskoot W, Schellekens H. 2010. Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol Sci 31(2):53-59.
22. Seefeldt MB, Rosendahl MS, Cleland JL, Hesterberg LK. 2009. Application of high hydrostatic pressure to dissociate aggregates and refold proteins. Curr Pharm Biotechnol 10(4):447-455.
23. Rifkin RA, Maggio ET, Dike S, Kerr DA, Levy M. 2011. n-Dodecyl-beta-d-maltoside inhibits aggregation of human interferon-beta-1b and reduces its immunogenicity. J Neuroimmune Pharmacol 6(1):158-162.
24. Van Beers MM, Gilli F, Schellekens H, Randolph TW, Jiskoot W. 2012. Immunogenicity of recombinant human interferon beta interacting with particles of glass, metal, and polystyrene. J Pharm Sci 101(1):187-199.
25. Runkel L, Meier W, Pepinsky RB, Karpusas M, Whitty A, Kimball K, Brickelmaier M, Muldowney C, Jones W, Goelz SE. 1998. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). Pharm Res 15(4):641-649.
26. Hawe A, Friess W. 2007. Stabilization of a hydrophobic recombinant cytokine by human serum albumin. J Pharm Sci 96(11):2987-2999.
27. Anraku M, Tsurusaki Y, Watanabe H, Maruyama T, Kragh-Hansen U, Otagiri M. 2004. Stabilizing mechanisms in commercial albumin preparations: Octanoate and N-acetyl-l-tryptophanate protect human serum albumin against heat and oxidative stress. Biochim Biophys Acta 1702(1):9-17.
28. Arthur KK, Gabrielson JP, Kendrick BS, Stoner MR. 2009. Detection of protein aggregates by sedimentation velocity analytical ultracentrifugation (SV-AUC): Sources of variability and their relative importance. J Pharm Sci 98(10):3522-3539.
29. Nelissen I, Martens E, Van den Steen PE, Proost P, Ronsse I, Opdenakker G. 2003. Gelatinase B/matrix metalloproteinase-9 cleaves interferon-beta and is a target for immunotherapy. Brain 126(Pt 6):1371-1381.
30. Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJ, Middaugh CR, Winter G. 2010. Potential inaccurate quantitation and sizing of protein aggregates by size exclusion chromatography: Essential need to use orthogonal methods to assure the quality of therapeutic protein products. J Pharm Sci 99(5):2200-2208.
31. Arakawa T, Ejima D, Li T, Philo JS. 2010. The critical role of mobile phase composition in size exclusion chromatography of protein pharmaceuticals. J Pharm Sci 99(4):1674-1692.
32. Singh SK, Afonina N, Awwad M, Bechtold-Peters K, Blue JT, Chou D, Cromwell M, Krause HJ, Mahler HC, Meyer BK, Narhi L, Nesta DP, Spitznagel T. 2010. An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics. J Pharm Sci 99(8):3302-3321.
33. Patel AR, Lau D, Liu J. 2012. Quantification and characterization of micrometer and submicrometer subvisible particles in protein therapeutics by use of a suspended microchannel resonator. Anal Chem 84(15):6833-6840.
34. Filipe V, Hawe A, Jiskoot W. 2010. Critical evaluation of nanoparticle tracking analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates. Pharm Res 27(5):796-810.
35. Thirumangalathu R, Krishnan S, Ricci MS, Brems DN, Randolph TW, Carpenter JF. 2009. Silicone oil- and agitation-induced aggregation of a monoclonal antibody in aqueous solution. J Pharm Sci 98(9):3167-3181.
36. Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A, Rutgeerts P. 2003. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348(7):601-608.
37. Pascual-Salcedo D, Plasencia C, Ramiro S, Nuno L, Bonilla G, Nagore D, Ruiz Del Agua A, Martinez A, Aarden L, Martin-Mola E, Balsa A. 2011. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford) 50(8):1445-1452.
38. Plasencia C, Pascual-Salcedo D, Nuno L, Bonilla G, Villalba A, Peiteado D, Diez J, Nagore D, Del Agua AR, Moral R, Martin-Mola E, Balsa A. 2012. Influence of immunogenicity on the efficacy of long-term treatment of spondyloarthritis with infliximab. Ann Rheum Dis 71(12):1955-1960
39. Bender NK, Heilig CE, Droll B, Wohlgemuth J, Armbruster FP, Heilig B. 2007. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int 27(3):269-274.
40. West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PC, van der Woude CJ. 2008. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther 28(9):1122-1126.
41. Getts DR, Getts MT, McCarthy DP, Chastain EML, Miller SD. 2010. Have we overestimated the benefit of human(ized) antibodies? Mabs-Austin 2(6):682-694.
42. Draper LR, Hirata AA. 1968. Antibody responses in rabbits to soluble and particulate forms of bovine serum albumin. Immunology 15(1):23-30.